|
 
- 现金
- 511 元
- 精华
- 0
- 帖子
- 201
- 注册时间
- 2008-12-19
- 最后登录
- 2017-4-5
|
本帖最后由 tanglang 于 2010-11-3 15:15 编辑
ID#
377
Location:
Hynes: Exhibit Hall C
Time of Presentation:
Oct 30 2:00 PM - 7:30 PM
Category:
R09. Hepatitis B: Treatment
Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/ seroconversion
Z. Cao1; Y. Zhang1; L. Ma1; Y. Jin1; H. Yu1; X. Zhang1; Y. Liu1; Y. Huang1; B. Ma1; S. Ren1; L. Wang1; X. Chen1; L. Wei1
1. Beijing Youan Hospital, Capital Medical University, Beijing, China.
Objective
To investigate the efficacy and safety of extended treatment with peginterferon alfa-2a [40KD] (PEG-IFN) in combination with lamivudine (LAM) or adefovir (ADV) for 96 weeks in Chinese patients with hepatitis ‘e’ antigen (HBeAg)-positive chronic hepatitis B (CHB).
Methods
A total of 47 consecutive patients with HBeAg-positive chronic hepatitis B were randomized to receive PEG-IFN 135 µg weekly in combination with either LAM 100 mg daily (N=24) or ADV 10 mg daily (N=23). All patients have currently completed 48 weeks of treatment; 20 patients in the PEG-IFN plus LAM group and 21 in PEG-IFN plus ADV group have completed 96 weeks of therapy. Virological response (HBV DNA <500 copies/mL; Biosystems 5700) and serological responses (HBeAg and HBsAg measured using Abbott ARCHITECT) were measured at 3 month intervals during treatment.
Results
The majority of patients were infected with hepatitis B virus (HBV) genotype B or C. By the end of 48 weeks of treatment, 45/47 patients (96%) achieved virological response. All of those patients who had completed 96 weeks of treatment (41/41) achieved a virological response. After 48 weeks of therapy, 12/24 (50%) of patients treated with PEG-IFN plus LAM and 10/23 (44%) of patients treated with PEG-IFN plus ADV achieved HBeAg seroconversion. Of those patients who had completed 96 weeks of therapy, 15/20 (75%) and 15/21 (71%) patients, respectively, in each group achieved HBeAg seroconversion.
In the PEG-IFN plus LAM group, HBsAg seroconversion rates were 8% after 48 weeks of treatment, rising to 30% in those patients who had completed 96 weeks of therapy. In the PEG-IFN plus ADV group, the rate of HBsAg seroconversion was 4% after 48 weeks and 24% after 96 weeks of treatment. Extended treatment to 96 weeks was well tolerated. The safety profile of 96 weeks of treatment was similar to that seen in patients treated for 48 weeks.
Conclusions
Extended treatment of PEG-IFN in combination with nucleos(t)ide analogs in patients with HBeAg-positive CHB appears to be a promising treatment strategy, resulting in high HBsAg seroconversion rates, the closest outcome to cure in the management of CHB.
药物的连用，96周达到30%和24%的表面抗原转阴。总算是有分母了，相比较当年在地坛医院的转阴者。
我把那些post的题目大约看了一遍，发现表面抗原的的定量,dynamics,清除已经是一个公开和普遍的话题了。比如，
453. HBsAg SEROCOVERSION UNDER LAMIVUDINE IN HBeAg-NEGATIVE CHRONIC HEPATITIS B
374.Long-term monitoring of HBsAg kinetics and prediction of HBsAg clearance in patients with chronic hepatitis B treated with nucleoside/nucleotide analogues S.
377. Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/ seroconversion
我觉得最终的治愈应该不远了。
大家珍重！ |
-
总评分: 现金 + 2
查看全部评分
|
发表于 2010-11-3 15:11
激动中
